Unlike other cancers requiring up to two years of immunotherapy, CSCC patients can achieve lasting responses after just a few months. This "less is more" approach is crucial for minimizing toxicity in the elderly, comorbid patient population, especially those with organ transplants.

Clinicians are far more cautious using immunotherapy in organ transplant recipients than in patients with autoimmune disease. The risk of irreversible graft rejection is a major deterrent, reserving checkpoint inhibitors only for when no other treatment options exist.

Data from older studies suggests that PI3K inhibitors and mTOR inhibitors (like everolimus) have distinct mechanisms and may not be cross-resistant. This allows clinicians to confidently sequence these agents, for example using everolimus after progression on a PI3K or AKT inhibitor, providing more lines of targeted therapy.

A patient's willingness to accept immunotherapy risk depends on the transplanted organ. Kidney transplant patients may proceed, knowing dialysis is a viable backup. For heart, lung, or liver transplant patients, rejection is life-threatening, often leading them to choose hospice over treatment.

Though typically contraindicated, checkpoint inhibitors can be used for transplant recipients with advanced skin cancer. This requires shared decision-making, collaboration with the transplant team, and a specific protocol involving high-dose pulse steroids to mitigate the high risk of allograft rejection.

The next frontier in CSCC isn't just about new drugs, but about optimizing existing ones. A key research area is determining the minimum number of immunotherapy doses required for an optimal response—potentially just one or two—to limit toxicity, reduce treatment burden, and personalize care for high-risk patients.

Using checkpoint inhibitors in renal transplant recipients requires extreme caution due to a significant risk of graft rejection, potentially leading to dialysis. This decision is a major trade-off and must involve a case-by-case discussion with the patient and a nephrologist.

The immunosuppressed population with CSCC faces a significantly higher risk of recurrence, metastasis, and death. Dr. Gross highlights this group as being particularly challenging and underserved by current research, indicating a critical need for more dedicated clinical data and tailored treatment strategies.

When counseling transplant patients about immunotherapy for CSCC, clinicians can cite retrospective data indicating a roughly 33% chance of organ rejection and a 20% chance of complete organ loss. This provides a clear, quantitative framework for informed consent and shared decision-making.